^
    3d
    A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms (clinicaltrials.gov)
    P1, N=100, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2028 --> Jan 2028
    Trial completion date • First-in-human
    18d
    ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE） (clinicaltrials.gov)
    P=N/A, N=22, Not yet recruiting, Tongji Hospital
    New trial
    |
    cyclophosphamide • ACE1831
    20d
    Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Acepodia Biotech, Inc. | Initiation date: Aug 2025 --> Jan 2026
    Trial initiation date
    |
    cyclophosphamide • ACE1831
    24d
    Aflac-NBL-2002: Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Emory University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    temozolomide • irinotecan • zoledronic acid • Unituxin (dinutuximab)
    25d
    Genetic engineering and allogeneic optimization of Vδ1 γδ CAR-T cells (ADI-270) for cancer immunotherapy. (PubMed, J Immunother Cancer)
    A recent study by Nishimoto et al showcased the adaptation of these engineering approaches to Vδ1 γδ T cells (ADI-270) by coexpressing a CD70-targeted CAR and a dominant-negative TGFβRII receptor (dnTGFβRII) to target CD70+ malignancies, addressing immunosuppression and host-versus-graft rejection. This commentary explores αβ T cell-derived engineering strategies applicable to γδ T cells, while also highlighting genome-editing innovations poised to advance next-generation γδ CAR-T development.
    Journal
    |
    CD70 (CD70 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
    26d
    EVICTION-2: Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=56, Completed, ImCheck Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin) • IPN60340
    1m
    EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=292, Active, not recruiting, ImCheck Therapeutics | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Oct 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    Keytruda (pembrolizumab) • IPN60340
    2ms
    ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Eureka Therapeutics Inc. | Phase classification: P2 --> P1/2
    Phase classification
    |
    GPC3 (Glypican 3)
    |
    cyclophosphamide • ECT204
    2ms
    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=11, Terminated, The First Affiliated Hospital with Nanjing Medical University | N=33 --> 11 | Trial completion date: Jun 2028 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jun 2025; Achieve the proof of concept.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    2ms
    CLN-619-001: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=440, Active, not recruiting, Cullinan Therapeutics Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • CLN-619
    2ms
    Optimization of velocity receptor transduction in CAR T cells. (PubMed, bioRxiv)
    We also observed a log-linear relationship between viral dose and transduction efficiency for a subset of VRs previously tested in various mouse models of human cancer, with VR5αIL8 and VR5αTNFα VRs consistently outperforming VR5αIL5 and V5 (full length native IL5 receptor). Overall, these findings establish an optimized and reproducible framework that offers valuable guidance for the future development and functional study of VR-CAR T cells in cellular therapies for solid tumors.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL5 (Interleukin 5)
    2ms
    B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma (clinicaltrials.gov)
    P1, N=14, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human